| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Daniel J Levitt last filed a Form 4 in May 2018, as Director at NGNE. Daniel J Levitt's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Daniel J Levitt has 8 Form 4 filings on record from March 2015 to May 2018, across 2 companies: Director at Neurogene (NGNE), 2015–2018; EVP and Chief Medical Officer at LadRx (LADX), 2015–2016.
The 9 reported transactions were 7 option or other derivative awards, 1 option exercise and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $49K.
The only open-market sale was 3,906 shares of NGNE at an average $12.67 on May 14, 2018, about $49K.
Shares as reported in the last Form 4 for each company; the most recent is from May 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 14, 2018 | NGNE Neurogene Inc. | Director | Sale+OE | 3,906 | $12.67 | $49,489.02 | - |